Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of VGX-3100 with CELLECTRA 5PSP for HPV-16/18-associated cervical HSIL
CTR20201547Phase 3Active
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Nov 2021
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bizalimogene ralaplasmid in cervical intraepithelial neoplasia (CIN), human papillomavirus infection, sponsored by Inovio Pharmaceuticals, Inc.. Started Nov 2021; status: active.
02
Drugs
bizalimogene ralaplasmid
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on CTR20201547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201547.